Rare Oncology News
Advertisement
5 Facts you should know about
CAR-T/multiple myeloma
1
BCMA-directed CAR-T induces high response rates in heavily pretreated myeloma though relapses are common over time
2
Selection considers prior IMiD/PI/anti-CD38 exposure, disease burden, and organ function; integrate with transplant/bispecific sequencing
3
Monitor for CRS/ICANS, prolonged cytopenias, infections; develop revaccination schedules after immune reconstitution
4
Bridging therapy and radiation may control disease pre-infusion; outpatient models depend on center protocols
5
Long-term follow-up addresses neurocognition, QoL, and options at relapse (bispecifics, clinical trials)